Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03150914 · ClinicalTrials.gov registry record · Phase 3

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

A Phase 3 study of Lymphangioleiomyomatosis and LAM, sponsored by University of Cincinnati.

Active
Registry status
Phase 3
Development phase
60
Enrollment target
8
Study locations

NCT03150914 is a Phase 3 study of Lymphangioleiomyomatosis and LAM that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 60 participants, below the 824-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03150914, a Phase 3 study of Lymphangioleiomyomatosis and LAM, is active but no longer recruiting, sponsored by University of Cincinnati.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
8
Study locations

Study Summary

This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.

Conditions Studied

Lymphangioleiomyomatosis LAM

Interventions

  • DRUG Sirolimus

Study Locations (8)

California

  • Stanford University - Palo Alto

Colorado

  • National Jewish Hospital - Denver

Georgia

  • Emory University - Atlanta

Illinois

  • Loyola University - Chicago

Massachusetts

  • Brigham and Woman's Hospital - Boston

Ohio

  • University of Cincinnati - Cincinnati

Pennsylvania

  • University of Pennsylvania - Philadelphia

Washington

  • Swedish Health - Seattle

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-01-01
Est. Completion 2025-06-30
Phase Phase 3

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03150914

The ClinicalTrials.gov registry entry for NCT03150914 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (93% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.

NCT03150914 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT03150914 about?

NCT03150914 is a clinical study titled "Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial". This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.

What is the current status of trial NCT03150914?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2018-01-01. Estimated completion is 2025-06-30.

What conditions does trial NCT03150914 study?

This clinical trial studies the following conditions: Lymphangioleiomyomatosis, LAM.

What interventions are being tested in trial NCT03150914?

The interventions under investigation include: Sirolimus (DRUG).

Who is sponsoring clinical trial NCT03150914?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03150914 being conducted?

This trial has 8 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphangioleiomyomatosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphangioleiomyomatosis

All registered trials for this condition

LAM

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.